High Collagen Type VI Formation Is a Strong and Independent Predictor of Poor Prognosis in HFpEF
Time: 2:00 pm
day: Conference Day 2
Details:
- HFpEF is a highly heterogenous disease & patient stratification is essential to inform clinical trial
- Meta-analysis data demonstrated strong, independent prognostic value of PRO-C6 as a novel biomarker in HFpEF (NEJM Evidence 2022)
- FDA issued Letter of Support (LoS) to encourage further PRO-C6 work in HFpEF
